Bootstrap Bio and Manhattan Genomics, two companies focused on human embryo editing to prevent genetic diseases, have ceased operations. The closures mark a setback for the controversial field of germline editing.
Bootstrap Bio and Manhattan Genomics have both shut down their operations, ending their respective efforts to develop human embryo editing technologies. The companies were among a small number of firms pursuing germline editing—modifications to embryos that would be inherited by future generations—primarily to prevent serious genetic conditions.
The reasons behind the closures were not immediately detailed, but the exits underscore the commercial and regulatory challenges facing the embryo editing sector. The field has faced intense scrutiny from bioethicists, policymakers, and the public since Chinese scientist He Jiankui's 2018 announcement of the first gene-edited babies, which triggered global controversy and criminal charges against him.
The U.S. and many other countries have restricted or banned germline editing in humans. While some researchers continue work on somatic gene therapy—editing non-reproductive cells—the commercial viability of human embryo editing remains highly uncertain.
ElevenLabs, TwelveLabs, and ThirteenLabs have launched with separate technological approaches. The trio's emergence signals continued fragmentation in the AI development landscape.
David Heinemeier Hansson has established the Omacom Foundation, a non-profit dedicated to supporting Omarchy, his Linux distribution. The initiative secured $8 million in funding from notable tech leaders including Michael Dell, Jack Dorsey, and Patrick Collison.
Runlayer and Rippling have dropped their lawsuits against each other with no settlement payments exchanged. Rippling marked the resolution by launching a competing product.
Japanese space startup Letara has secured ¥2.6 billion ($16 million) in funding to expand its hybrid rocket technology beyond satellite thrusters into broader defense and security applications.